Difference between revisions of "Template:Health risks in the conjugated estrogens and medroxyprogesterone acetate substudy of the Women's Health Initiative"

From blackwiki
Jump to navigation Jump to search
(Remove abbreviations from table cell: Already marked up with Template:Abbr for screen readers.)
imported>Medgirl131
 
(16 intermediate revisions by 4 users not shown)
Line 1: Line 1:
{| class="wikitable sortable mw-collapsible {{{state<includeonly>|mw-collapsed</includeonly>}}}"
+
#REDIRECT [[Template:Results of the Women's Health Initiative menopausal hormone therapy randomized controlled trials]]
|+ class="nowrap" | {{Navbar|Health risks in the conjugated estrogens and medroxyprogesterone acetate substudy of the Women's Health Initiative|mini=y}} Health risks in the {{abbr|CEEs|conjugated estrogens}}/{{abbr|MPA|medroxyprogesterone acetate}} substudy of the Women's Health Initiative
 
|-
 
! rowspan="2" | Event !! rowspan="2" style="width: 205px;" | Relative Risk {{abbr|CEEs|Conjugated estrogens}}/{{abbr|MPA|Medroxyprogesterone acetate}} vs. placebo at 5.2 years (95% {{abbr|CI|confidence interval}}{{NoteTag|Nominal confidence intervals unadjusted for multiple looks and multiple comparisons.}}) !! style="width: 75px;" data-sort-type="number" | Placebo<br />(n = 8102) !! style="width: 75px;" data-sort-type="number" | {{abbr|CEEs|Conjugated estrogens}}/{{abbr|MPA|Medroxyprogesterone acetate}}<br />(n = 8506)
 
|-
 
! colspan="2" | Absolute Risk per 10,000 Women-Years
 
|-
 
| [[Coronary heart disease]] events<br />({{dfn|non-fatal [[myocardial infarction]]}}, {{dfn|death|Coronary heart disease death|}}) || 1.29 (1.02–1.63)<br />1.32 (1.02–1.72)<br />1.18 (0.70–1.97) || 30<br />23<br />6 || 37<br />30<br />7
 
|-
 
| [[Invasive breast cancer]]{{efn|Includes metastatic and non-metastatic breast cancer with the exception of in situ breast cancer.}} || 1.26 (1.00–1.59) || 30 || 38
 
|-
 
| [[Stroke]] || 1.41 (1.07–1.85) || 21 || 29
 
|-
 
| [[Pulmonary embolism]] || 2.13 (1.39–3.25) || 8 || 16
 
|-
 
| [[Colorectal cancer]] || 0.63 (0.43–0.92) || 16 || 10
 
|-
 
| [[Endometrial cancer]] || 0.83 (0.47–1.47) || 6 || 5
 
|-
 
| [[Hip fracture]] || 0.66 (0.45–0.98) || 15 || 10
 
|-
 
| Death due to causes other than above || 0.92 (0.74–1.14) || 40 || 37
 
|-
 
| Global Index{{efn|A subset of the events was combined in a "global index", defined as the earliest occurrence of coronary heart disease events, invasive breast cancer, stroke, pulmonary embolism, endometrial cancer, colorectal cancer, hip fracture, or death due to other causes.}} || 1.15 (1.03–1.28) || 151 || 170
 
|-
 
| [[Deep vein thrombosis]]{{efn|name=not-gi|Not included in Global Index.}} || 2.07 (1.49–2.87) || 13 || 26
 
|-
 
| [[Vertebral fracture]]s{{efn|name=not-gi}} || 0.66 (0.44–0.98) || 15 || 9
 
|-
 
| Other [[osteoporotic fracture]]s{{efn|name=not-gi}} || 0.77 (0.69–0.86) || 170 || 131
 
|- class="sortbottom"
 
| colspan="10" style="width: 1px;" | '''Sources:''' <ref name="EstraceLabel">{{cite web | url=http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/081295s014,084499s042,084500s044lbl.pdf | title=ESTRACE TABLETS, (estradiol tablets, USP) | author=Warner Chilcott | authorlink=Warner Chilcott | date=March 2005 | publisher=fda.gov | format=PDF | accessdate=27 November 2016 }}</ref><ref name="pmid12117397">{{cite journal | vauthors = Rossouw JE, Anderson GL, [[Ross Prentice|Prentice RL]], LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J | title = Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial | journal = JAMA | volume = 288 | issue = 3 | pages = 321–33 | date = July 2002 | pmid = 12117397 | doi = 10.1001/jama.288.3.321 | url = }}</ref>
 
|}<!--
 
 
 
--><noinclude>
 
==Notes and references==
 
{{Reflist}}
 
{{Notelist}}
 
{{Notefoot}}
 
[[Category:Medication templates]]
 
[[Category:Templates that generate named references]]
 
</noinclude>
 

Latest revision as of 10:15, 4 March 2020